X
[{"orgOrder":0,"company":"Alcresta Therapeutics","sponsor":"Linden Capital Partners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Linden Capital Partners Acquires Alcresta Therapeutics, Inc.","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals by Alcresta Therapeutics
Filters
Companies By Therapeutic Area
Details:
Alcresta Therapeutics has developed a novel enzyme-based (iLipase) platform, including ALC-079, which is being investigated for the Neonatal Intensive Care Unit for pancreatic immaturity.
Lead Product(s):
ALC-079
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Product Name: ALC-079
Highest Development Status: Undisclosed
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Linden Capital Partners
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Acquisition
March 12, 2024